Apatinib improves survival in advanced HCC patients undergoing TACE
Treatment with the tyrosine kinase inhibitor apatinib, in combination with transcatheter arterial chemoembolization (TACE), yields survival gains in advanced hepatocellular carcinoma (HCC) patients with tumour thrombus in the first- and lower-order portal vein branches, according to a retrospective study. Safety needs to be monitored during application despite the manageable adverse events.